Ilumya Alternatives Compared
| Ilumya | Cosentyx | Taltz |
|
|---|
| Ilumya (tildrakizumab) | Cosentyx (secukinumab) | Taltz (ixekizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ilumya is administered by subcutaneous injection every 12 weeks (after an initial loading dose) and may be used to reduce inflammation associated with psoriasis but it needs to be administered by a... View more |
Prescription only
Cosentyx may be used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and some other conditions. After an initial loading dose, Cosentyx needs to be injected subcutaneously... View more |
Prescription only
Taltz is a monoclonal antibody that reduces inflammation and may be used to treat conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis. It is given by injection just under the... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Ilumya (tildrakizumab) | More about Cosentyx (secukinumab) | More about Taltz (ixekizumab) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
No lower-cost generic available |
||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Ilumya has an average rating of 5.2 out of 10 from a total of 6 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 50% reported a negative effect. |
Cosentyx has an average rating of 6.1 out of 10 from a total of 233 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 33% reported a negative effect. |
Taltz has an average rating of 6.9 out of 10 from a total of 190 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 25% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Ilumya side effects in more detail. |
Common side effects include:
See also: Cosentyx side effects in more detail. |
See also: Taltz side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Ilumya prices |
View all Cosentyx prices |
View all Taltz prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
552 hours |
744 hours |
312 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 155 drugs are known to interact with Ilumya:
|
A total of 210 drugs are known to interact with Cosentyx:
|
A total of 210 drugs are known to interact with Taltz:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
March 20, 2018 |
January 21, 2015 |
March 22, 2016 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.